Prophylactic recombinant epoetin alfa markedly reduces the need for blood transfusion in patients with metastatic melanoma treated with biochemotherapy

Cytokines, Cellular and Molecular Therapy

Volumn 5, Issue 4, 1999, Pages 205-206

  Wolchok, Jedd D ^a   Klimek, Virginia M ^a   Williams, Linda ^a   Chapman, Paul B ^a,b  

^a Department of Medicine   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Anemia; Biochemotherapy; Erythropoietin; Melanoma

Indexed keywords

ALPHA INTERFERON; CISPLATIN; DACARBAZINE; INTERLEUKIN 2; RECOMBINANT ERYTHROPOIETIN; VINBLASTINE;

ANEMIA; ARTICLE; BLOOD TRANSFUSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MELANOMA; PRIORITY JOURNAL;

ANEMIA; BLOOD TRANSFUSION; COST-BENEFIT ANALYSIS; DRUG THERAPY; EPOETIN ALFA; HEMATINICS; HUMANS; MELANOMA; NEOPLASM METASTASIS; QUALITY OF LIFE;

EID: 0033498577     PISSN: 13684736     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Klimek VM, Wolchok JD, Poo-Hwu W-J et al, Chemotherapy for melanoma. Dermatol Ther (1999) 10: 26-39.
2. Legha S, Ring S, Plager C et al, Biochemotherapy using interleukin-2 (IL-2) + Interferon alfa 2-A (IFN) in combination with cisplatin (C), vinblastine (V) and DTIC (D) in advanced melanoma. Proc Am Soc Clin Oncol (1991) 10: 293.
3. Khayat D, Borel C, Tourani JM et al, Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. J Clin Oncol (1993) 11: 2173-80.
4. Legha S, Ring S, Bedikian A et al, Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-α. Ann Oncol (1996) 7: 827-35.
5. McDermott DF, Mier JW, Lawrence DP et al, A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine (CVD), interleukin-2 (LL-2) and interferon alpha-2b (IFN) in patients with metastatic melanoma. Proc Am Soc Clin Oncol (1998) 17: 507A.
6. O'Day SJ, Gammon G, Boasberg PD et al, Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma. J Clin Oncol (1999) 17: 2752-61.
7. Ortega A, Dranitsaris G, Puodziunas AL, What are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis. Cancer (1998) 83: 2588-96.
8. Glaspy J, Bukowski R, Steinberg D et al, Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol (1997) 15: 1218-34.
9. Del Mastro L, Venturini M, Strategies for the use of epoietin alfa in breast cancer patients. Oncologist (1998) 3: 314-18.
10. Thatcher N, De Campos ES, Bell DR et al, Epoetin alfa prevents anemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. Br J Cancer (1999) 80: 396-402.